效应性T细胞共刺激分子OX40的治疗靶向作用 - Suppr

Suppr

超能文献

Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40.

作者信息

Sugamura Kazuo, Ishii Naoto, Weinberg Andrew D

机构信息

Department of Microbiology and Immunology, Tohoku University Graduate School of Medicine, Sendai 980-8575, Japan.

出版信息

Nat Rev Immunol. 2004 Jun;4(6):420-31. doi: 10.1038/nri1371.

DOI:10.1038/nri1371

PMID:15173831

Abstract

摘要

相似文献

Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40.

Nat Rev Immunol. 2004 Jun;4(6):420-31. doi: 10.1038/nri1371.

Identification of OX40 ligand and preliminary characterization of its activities on OX40 receptor.

Circ Shock. 1994 Sep;44(1):30-4.

Co-stimulatory agonists as immunological adjuvants.

Vaccine. 2006 Apr 24;24(17):3399-407. doi: 10.1016/j.vaccine.2006.02.022. Epub 2006 Feb 24.

Contribution of CD30/CD153 but not of CD27/CD70, CD134/OX40L, or CD137/4-1BBL to the optimal induction of protective immunity to Mycobacterium avium.

J Leukoc Biol. 2004 Nov;76(5):1039-46. doi: 10.1189/jlb.1103572. Epub 2004 Aug 17.

Characterization and application of two novel monoclonal antibodies against human OX40: costimulation of T cells and expression on tumor as well as normal gland tissues.

Tissue Antigens. 2006 Apr;67(4):307-17. doi: 10.1111/j.1399-0039.2006.00584.x.

Regulation of CD4 T cell memory by OX40 (CD134).

Vaccine. 2006 Feb 13;24(7):872-83. doi: 10.1016/j.vaccine.2005.07.108. Epub 2005 Sep 7.

Roles of OX40 in the development of murine experimental allergic conjunctivitis: exacerbation and attenuation by stimulation and blocking of OX40.

Invest Ophthalmol Vis Sci. 2006 Feb;47(2):657-63. doi: 10.1167/iovs.05-1064.

The adjuvant effects of co-stimulatory molecules on cellular and memory responses to HBsAg DNA vaccination.

J Gene Med. 2007 Feb;9(2):136-46. doi: 10.1002/jgm.1004.

Endothelial cell co-stimulation through OX40 augments and prolongs T cell cytokine synthesis by stabilization of cytokine mRNA.

Int Immunol. 2005 Jun;17(6):737-47. doi: 10.1093/intimm/dxh255. Epub 2005 May 20.

OX40 (CD134) engagement drives differentiation of CD4+ T cells to effector cells.

Eur J Immunol. 2006 May;36(5):1093-103. doi: 10.1002/eji.200535637.

引用本文的文献

First-in-human phase I/II, open-label study of mRNA-2416 alone or combined with durvalumab in patients with advanced solid tumors and ovarian cancer.

Oncologist. 2025 Jun 4;30(6). doi: 10.1093/oncolo/oyaf115.

Emerging Immunotherapy Targets in Early Drug Development.

Int J Mol Sci. 2025 Jun 4;26(11):5394. doi: 10.3390/ijms26115394.

ROCKET: a phase 3 program evaluating the efficacy and safety of rocatinlimab in moderate-to-severe atopic dermatitis.

Immunotherapy. 2025 Feb;17(2):83-94. doi: 10.1080/1750743X.2025.2464528. Epub 2025 Feb 26.

Generation and characterization of OX40-ligand fusion protein that agonizes OX40 on T-Lymphocytes.

Front Immunol. 2025 Jan 10;15:1473815. doi: 10.3389/fimmu.2024.1473815. eCollection 2024.

A Phase I Clinical Trial Adding OX40 Agonism to In Situ Therapeutic Cancer Vaccination in Patients with Low-Grade B-cell Lymphoma Highlights Challenges in Translation from Mouse to Human Studies.

Clin Cancer Res. 2025 Mar 3;31(5):868-880. doi: 10.1158/1078-0432.CCR-24-2770.

Making the effect visible - OX40 targeting nanobodies for imaging of activated T cells.

Front Immunol. 2024 Oct 15;15:1480091. doi: 10.3389/fimmu.2024.1480091. eCollection 2024.

Targeting post-translational modifications of Foxp3: a new paradigm for regulatory T cell-specific therapy.

Front Immunol. 2023 Oct 23;14:1280741. doi: 10.3389/fimmu.2023.1280741. eCollection 2023.

OX40 (CD134) Expression on T Regulatory Cells Is Related to Serious Hypertensive Disorders in Pregnancy.

J Cardiovasc Dev Dis. 2023 Oct 17;10(10):431. doi: 10.3390/jcdd10100431.

YAP1 expression is associated with survival and immunosuppression in small cell lung cancer.

Cell Death Dis. 2023 Sep 26;14(9):636. doi: 10.1038/s41419-023-06053-y.

Lung tumor-infiltrating T have divergent transcriptional profiles and function linked to checkpoint blockade response.

Sci Immunol. 2023 Sep 15;8(87):eadg1487. doi: 10.1126/sciimmunol.adg1487.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40.

作者信息

Sugamura Kazuo, Ishii Naoto, Weinberg Andrew D

机构信息

Department of Microbiology and Immunology, Tohoku University Graduate School of Medicine, Sendai 980-8575, Japan.

出版信息

Nat Rev Immunol. 2004 Jun;4(6):420-31. doi: 10.1038/nri1371.

DOI:10.1038/nri1371

PMID:15173831

Abstract

摘要

相似文献

Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40.

Nat Rev Immunol. 2004 Jun;4(6):420-31. doi: 10.1038/nri1371.

Identification of OX40 ligand and preliminary characterization of its activities on OX40 receptor.

Circ Shock. 1994 Sep;44(1):30-4.

Co-stimulatory agonists as immunological adjuvants.

Vaccine. 2006 Apr 24;24(17):3399-407. doi: 10.1016/j.vaccine.2006.02.022. Epub 2006 Feb 24.

Contribution of CD30/CD153 but not of CD27/CD70, CD134/OX40L, or CD137/4-1BBL to the optimal induction of protective immunity to Mycobacterium avium.

J Leukoc Biol. 2004 Nov;76(5):1039-46. doi: 10.1189/jlb.1103572. Epub 2004 Aug 17.

Characterization and application of two novel monoclonal antibodies against human OX40: costimulation of T cells and expression on tumor as well as normal gland tissues.

Tissue Antigens. 2006 Apr;67(4):307-17. doi: 10.1111/j.1399-0039.2006.00584.x.

Regulation of CD4 T cell memory by OX40 (CD134).

Vaccine. 2006 Feb 13;24(7):872-83. doi: 10.1016/j.vaccine.2005.07.108. Epub 2005 Sep 7.

Roles of OX40 in the development of murine experimental allergic conjunctivitis: exacerbation and attenuation by stimulation and blocking of OX40.

Invest Ophthalmol Vis Sci. 2006 Feb;47(2):657-63. doi: 10.1167/iovs.05-1064.

The adjuvant effects of co-stimulatory molecules on cellular and memory responses to HBsAg DNA vaccination.

J Gene Med. 2007 Feb;9(2):136-46. doi: 10.1002/jgm.1004.

Endothelial cell co-stimulation through OX40 augments and prolongs T cell cytokine synthesis by stabilization of cytokine mRNA.

Int Immunol. 2005 Jun;17(6):737-47. doi: 10.1093/intimm/dxh255. Epub 2005 May 20.

OX40 (CD134) engagement drives differentiation of CD4+ T cells to effector cells.

Eur J Immunol. 2006 May;36(5):1093-103. doi: 10.1002/eji.200535637.

引用本文的文献

First-in-human phase I/II, open-label study of mRNA-2416 alone or combined with durvalumab in patients with advanced solid tumors and ovarian cancer.

Oncologist. 2025 Jun 4;30(6). doi: 10.1093/oncolo/oyaf115.

Emerging Immunotherapy Targets in Early Drug Development.

Int J Mol Sci. 2025 Jun 4;26(11):5394. doi: 10.3390/ijms26115394.

ROCKET: a phase 3 program evaluating the efficacy and safety of rocatinlimab in moderate-to-severe atopic dermatitis.

Immunotherapy. 2025 Feb;17(2):83-94. doi: 10.1080/1750743X.2025.2464528. Epub 2025 Feb 26.

Generation and characterization of OX40-ligand fusion protein that agonizes OX40 on T-Lymphocytes.

Front Immunol. 2025 Jan 10;15:1473815. doi: 10.3389/fimmu.2024.1473815. eCollection 2024.

A Phase I Clinical Trial Adding OX40 Agonism to In Situ Therapeutic Cancer Vaccination in Patients with Low-Grade B-cell Lymphoma Highlights Challenges in Translation from Mouse to Human Studies.

Clin Cancer Res. 2025 Mar 3;31(5):868-880. doi: 10.1158/1078-0432.CCR-24-2770.

Making the effect visible - OX40 targeting nanobodies for imaging of activated T cells.

Front Immunol. 2024 Oct 15;15:1480091. doi: 10.3389/fimmu.2024.1480091. eCollection 2024.

Targeting post-translational modifications of Foxp3: a new paradigm for regulatory T cell-specific therapy.

Front Immunol. 2023 Oct 23;14:1280741. doi: 10.3389/fimmu.2023.1280741. eCollection 2023.

OX40 (CD134) Expression on T Regulatory Cells Is Related to Serious Hypertensive Disorders in Pregnancy.

J Cardiovasc Dev Dis. 2023 Oct 17;10(10):431. doi: 10.3390/jcdd10100431.

YAP1 expression is associated with survival and immunosuppression in small cell lung cancer.

Cell Death Dis. 2023 Sep 26;14(9):636. doi: 10.1038/s41419-023-06053-y.

Lung tumor-infiltrating T have divergent transcriptional profiles and function linked to checkpoint blockade response.

Sci Immunol. 2023 Sep 15;8(87):eadg1487. doi: 10.1126/sciimmunol.adg1487.